Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
Aligos Therapeutics (Nasdaq: ALGS) will release its third quarter 2025 financial results on Thursday, November 6, 2025 before the U.S. market opens. The company is a clinical-stage biotech focused on therapies for liver and viral diseases. Investors can expect a routine pre-market earnings release and any accompanying commentary or webcast details to be announced separately.
Aligos Therapeutics (Nasdaq: ALGS) rilascerà i suoi risultati finanziari del terzo trimestre 2025 il giovedì 6 novembre 2025 prima dell'apertura del mercato USA. L'azienda è una biotecnologia in fase clinica focalizzata su terapie per malattie del fegato e virali. Gli investitori possono aspettarsi un rilascio routine dei guadagni pre-mercato e qualsiasi commento o dettagli della webcast verranno annunciati separatamente.
Aligos Therapeutics (Nasdaq: ALGS) publicará sus resultados financieros del tercer trimestre de 2025 el jueves 6 de noviembre de 2025 antes de la apertura del mercado de Estados Unidos. La empresa es una biotecnología en etapa clínica centrada en terapias para enfermedades del hígado y virales. Los inversionistas pueden esperar un habitual comunicado de resultados antes de la apertura y cualquier comentario o detalles de la webcast se anunciarán por separado.
Aligos Therapeutics (Nasdaq: ALGS)는 2025년 3분기 재무 결과를 미국 시장 개장 전인 2025년 11월 6일 목요일에 발표할 예정입니다. 이 회사는 간 및 바이러스 질환 치료제를 개발하는 임상 단계의 생명공학 기업입니다. 투자자들은 일반적인 프리마켓 실적 발표와 동반하는 해설이나 웹캐스트 세부 정보가 별도로 발표될 것으로 기대할 수 있습니다.
Aligos Therapeutics (Nasdaq : ALGS) publiera ses résultats financiers du troisième trimestre 2025 le jeudi 6 novembre 2025 avant l'ouverture du marché américain. L'entreprise est une biotechnologie en phase clinique centrée sur des thérapies pour les maladies du foie et virales. Les investisseurs peuvent s'attendre à un communiqué des résultats pré-marché habituel et tout commentaire ou détails du webcast seront annoncés séparément.
Aligos Therapeutics (Nasdaq: ALGS) wird seine Finanzergebnisse des dritten Quartals 2025 am Donnerstag, dem 6. November 2025 vor der Eröffnung des US-Marktes bekannt geben. Das Unternehmen ist ein klinisch tätiges Biotech-Unternehmen, das sich auf Therapien für Leber- und Viruserkrankungen konzentriert. Investoren können eine routinemäßige Pre-Market-Ergebnisveröffentlichung erwarten, und etwaige begleitende Kommentare oder Webcastspezifikationen werden separat angekündigt.
Aligos Therapeutics (Nasdaq: ALGS) ستصدر نتائجها المالية للربع الثالث من 2025 يوم الخميس 6 نوفمبر 2025 قبل افتتاح السوق الأمريكية. الشركة هي شركة تكنولوجيا حيوية في مرحلة إكلينيكية تركز على العلاجات لأمراض الكبد والفيروسات. يمكن للمستثمرين توقع إصدار أرباح ما قبل السوق بشكل روتيني وأي تعليقات مصاحبة أو تفاصيل البث المباشر ستعلن بشكل منفصل.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s third quarter 2025 financial results on Thursday, November 6, 2025, before the open of the U.S. financial markets.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Company
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
(650) 910-0427
jtarazi@Aligos.com
FAQ
When will Aligos Therapeutics (ALGS) report Q3 2025 results?
What is the ticker symbol for Aligos Therapeutics reporting Q3 2025?
Will Aligos Therapeutics provide a webcast or conference call for the Q3 2025 results?
What should investors expect from Aligos Therapeutics' November 6, 2025 release?
How can I obtain Aligos Therapeutics' Q3 2025 press release on November 6, 2025?
Does the October 30, 2025 announcement indicate clinical data will be released with Q3 2025 results?
